Casopitant

Casopitant (INNTooltip International Nonproprietary Name),^: 208 former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK₁ receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. It was under development by GlaxoSmithKline. In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary. However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.

References

1. Aprepitant
2. Antiemetic
3. NK1 receptor antagonist
4. Netupitant/palonosetron
5. Maropitant
6. Substance P
7. Fezolinetant
8. Elinzanetant
9. Fosaprepitant
10. List of investigational antidepressants
11. ATC code A04
12. Tachykinin receptor 1
13. Netupitant
14. Neurokinin B
15. Pavinetant
16. List of drugs: C–Ca
17. Tachykinin peptides
18. Ibodutant
19. Vestipitant
20. Nepadutant